Generate Biomedicines (GENB) Stock Price, News & Analysis
Company Description
Generate Biomedicines, Inc. develops protein therapeutics using a generative biology platform that applies machine learning to drug discovery and development. The company is a clinical-stage biotechnology issuer focused on programming novel protein medicines across therapeutic areas and modalities. Its common stock trades on Nasdaq under the symbol GENB.
The company reports a single operating segment engaged in generative biology. Its Generate Platform is designed to create and optimize protein therapeutic candidates by using computational methods to generate medicines across multiple modalities. Generate's operating model centers on advancing internally developed and partnered programs from platform discovery into clinical development.
Pipeline and therapeutic focus
Generate Biomedicines' named product candidates include GB-0895, an anti-TSLP program being developed for respiratory diseases including severe asthma and COPD; GB-4362, an MMAE neutralizer in oncology that has received FDA Fast Track designation; and GB-5267, a MUC16 armored CAR T program developed in collaboration with Roswell Park Comprehensive Cancer Center. These programs reflect the company's use of generative biology across different therapeutic modalities, including antibody-based and cellular therapy approaches.
The company's business is centered on research and development rather than commercial product sales. As a clinical-stage biotechnology company, its recurring activities include platform development, preclinical and clinical program advancement, regulatory interactions, collaboration work, and financing of research and development operations.
Public-company structure
Generate Biomedicines became a public company through an initial public offering of common stock. In connection with the IPO, the company adopted an amended and restated certificate of incorporation and amended and restated bylaws that define its public-company governance framework, authorized capital structure, stockholder meeting procedures, and board authority to issue undesignated preferred stock. The company is based in Somerville, Massachusetts.
Stock Performance
Generate Biomedicines (GENB) stock last traded at $13.90, down 0.83% from the previous close. Over the past 12 months, the stock has gained 9.9%. At a market capitalization of $1.8B, GENB is classified as a small-cap stock with approximately 128.2M shares outstanding.
GENB Rankings
Latest News
Generate Biomedicines has 4 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 1 with negative movement. Key topics include earnings, IPO, offering. View all GENB news →
SEC Filings
Generate Biomedicines has filed 5 recent SEC filings, including 2 Form SCHEDULE 13G, 1 Form 3, 1 Form 10-Q, 1 Form 8-K. The most recent filing was submitted on May 15, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all GENB SEC filings →
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Generate Biomedicines (GENB) currently stands at 5.9 million shares, up 30.1% from the previous reporting period, representing 6.0% of the float. Over the past 12 months, short interest has increased by 562.3%.
Days to Cover History
Days to cover for Generate Biomedicines (GENB) currently stands at 4.0 days, down 16.7% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has increased 303% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 1.0 to 9.7 days.
GENB Company Profile & Sector Positioning
Generate Biomedicines (GENB) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ. In monthly performance, the stock ranks #3,500 among all tracked companies.